A study to investigate the triple combination of PTI-801, PTI-808 and PTI-428 in patients with cystic fibrosis

Trial Profile

A study to investigate the triple combination of PTI-801, PTI-808 and PTI-428 in patients with cystic fibrosis

Planning
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2018

At a glance

  • Drugs PTI 428 (Primary) ; PTI 808 (Primary) ; PTI-801 Proteostasis Therapeutics (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Proteostasis Therapeutics
  • Most Recent Events

    • 10 Jan 2018 New trial record
    • 08 Jan 2018 According to a Proteostasis Therapeutics media release, Patrick A. Flume, MD, Professor of Medicine and Pediatrics and Director of the Cystic Fibrosis Center at the Medical University of South Carolina is the Lead Principal Investigator for PTI's triple combination program.
    • 08 Jan 2018 According to a Proteostasis Therapeutics media release, dosing is expected to initiate in the first half of 2018 and initial data from the trial are expected in the second half of 201.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top